# HOVON 150 AML (NCT03839771)

> A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

No report yet. It can be ordered.

- Drugs tested: ivosidenib; enasidenib
- Indication: IDH1/IDH2-mutated acute myeloid leukemia or myelodysplastic syndrome EB2

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03839771
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
- Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
- Interventions: AG-120; Placebo for AG-120; AG-221; Placebo for AG-221
- Enrollment: 968
- Primary outcome: Event-free survival (EFS)

## Indexed commentary on HOVON 150 AML so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 YouTube video
- 1 post on Bluesky

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=hovon-150-aml-nct03839771